The FDA expanded Mounjaro's label on August 28, 2026 for adults with type 2 diabetes at high cardiovascular risk.
The new indication covers reducing major cardiovascular events. These events include cardiovascular death, a nonfatal heart attack, or a nonfatal stroke.
This approval applies to Mounjaro, the tirzepatide brand for type 2 diabetes. It does not add the same cardiovascular indication to Zepbound, the tirzepatide brand for weight management.
SURPASS-CVOT compared Mounjaro with an active treatment
The approval rests on SURPASS-CVOT, a phase 3 trial with 13,299 adults. All participants had type 2 diabetes and established cardiovascular disease.
Researchers assigned participants by chance to weekly Mounjaro or weekly dulaglutide, sold as Trulicity. Neither participants nor researchers knew the assignment during the trial.
Dulaglutide was an active comparison drug with established cardiovascular benefit. The study therefore tested Mounjaro against another treatment, not an inactive placebo.
Follow-up lasted a median of 210.1 weeks, or about four years. A first major cardiovascular event occurred in 803 Mounjaro participants and 863 dulaglutide participants.
Those totals equal 12.1% with Mounjaro and 13.0% with dulaglutide. The observed absolute difference was 0.9 percentage point.
The trial established noninferiority, not a win over dulaglutide
The trial was designed to test noninferiority. This means Mounjaro had to stay within a preset margin of dulaglutide's cardiovascular result.
The hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01. A hazard ratio below 1 favors Mounjaro.
However, the confidence interval crossed 1.0. The FDA label states that superiority to dulaglutide was not established.
Results for cardiovascular death, nonfatal heart attack, and nonfatal stroke each had confidence intervals that crossed 1.0. The trial therefore did not prove a separate benefit for any single component.
The new label has a defined population and existing safety limits
The label covers adults with type 2 diabetes who face high cardiovascular risk. The trial itself enrolled people with established cardiovascular disease, a more specific group.
The approval does not establish cardiovascular benefit for people without type 2 diabetes. It also does not create a cardiovascular indication for Zepbound.
Mounjaro's existing warnings and contraindications still apply. The label includes a boxed warning about thyroid C-cell tumors seen in rats, with uncertain relevance to humans.
It also lists warnings for pancreatitis, low blood sugar with certain diabetes medicines, severe digestive reactions, and other risks. The cardiovascular approval does not remove those safety considerations.
Educational information only. This brief is not medical advice. Do not start, stop, or change treatment based on it.
Reporting note
OTN reviewed the linked sources and documents listed above. The article identifies estimates, projections, unresolved questions, and the limits of the evidence.
Editorial standards, corrections, and commerce disclosure · About BariatricPal · About the brief author · Contact BariatricPal